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Figure 1. Panels A+C abd B+D illustrate respective dose 
distribution for Plan1 and Plan2 for one patient case. 
 
 
Conclusions: A differential target and dose prescription 
strategy was technically feasible with LDR-BT seed planning 
and resulted in a significant dose reduction to both urethra 
and bladder neck, as compared to standard clinical dose 
planning.  
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Purpose/Objective: Focal brachytherapy (BT) is investigated 
as an alternative to whole gland BT for salvage treatment of 
recurrent prostate cancer to potentially improve functional 
outcome while maintaining cancer control. The aim of this 
study was to evaluate feasibility and toxicity of such 
treatment using high-dose-rate (HDR) brachytherapy. 
Materials and Methods: Seventeen patients were included in 
this prospective pilot study from May 2012 to July 2014. All 
the patients had received primary external beam 
radiotherapy with total dose of 70-78 Gy and experienced 
biochemical failure according to Phoenix criteria. Inclusion 
criteria were PSA <10 at inclusion, no detectable metastases 
on FACBC-PET-CT or pelvic MRI and a visible relapse tumour 
on FACBC-PET-CT or multiparametric MRI. All patients 
performed a bone marrow aspiration to assess the presence 
of micrometastatic disease in bone marrow. The salvage BT 
was delivered in 3 fractions with planning aim of 10 Gy to the 
tumour volume. For each fraction, separated by two weeks, 
the needles were applied using transrectal ultrasound (US) 
guidance. The gross tumour volume (GTV) was delineated in 
the US images based the on pre-treatment MR and FACBC-
PET-CT imaging. The urethra and the rectum wall were also 
delineated. Intra-operative treatment planning optimisation 
was performed for each fraction. Dose-volume-histogram 
parameters were found and 2Gy-eqivalent (EQD2) total dose 
were calculated using the LQ-model. The toxicity was scored 
using the EORTC/RTOG scale. 
Results: The median age of the patients was 69 years (range: 
60-75). Table 1 summarises the key dosimetry parameters 
achieved for this study. The GTV was in average 24% the 
whole prostate gland (range: 6-56). For all the patients the 
GTV D90 was above the total planning aim of 78 Gy (EQD2, 
α/β = 3). 
 
 
 
There were a significant correlation between the number of 
needles used and the volume of the GTV (R2 = 0.39, p<0.001). 
However, no correlation was found between the number of 
needles and the GTV D90, or between the volume of the GTV 
and the GTV D90. 
The median follow-up was 9 months (range: 3-21). Three 
patients (16%) experienced grade 2 genitourinary (GU) or 
gastrointestinal (GI) symptoms (GU urge, pollakisuria and 
urine leakage). Only one patient reported grade 3 
pollakisuria. In Figure 1 the GU and GI toxicity grades are 
plotted against the total EQD2 dose for rectum D2cm3 and 
urethra D0.1cm3.  
 
Conclusions: Our results suggest that focal HDR salvage 
brachytherapy is feasible with a GTV D90 above the planning 
aim for all the patients. The toxicity was acceptable; 
however, longer follow up is needed.  
  
 
Poster Discussion: Intrafraction and interfraction 
management  
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Purpose/Objective: Respiratory motion cause significant 
dose errors in IMPT for lung cancer patients due to induced 
variations in range and the interplay effect. The aim of this 
study was to investigate the relation between the respiratory 
amplitude and the dose errors due to the these effects.  
Materials and Methods: Intensity-modulated proton therapy 
(IMPT) plans with co-planar beam directions perpendicular to 
